AU3146997A - Pediatric formulation for hiv protease inhibitors - Google Patents

Pediatric formulation for hiv protease inhibitors

Info

Publication number
AU3146997A
AU3146997A AU31469/97A AU3146997A AU3146997A AU 3146997 A AU3146997 A AU 3146997A AU 31469/97 A AU31469/97 A AU 31469/97A AU 3146997 A AU3146997 A AU 3146997A AU 3146997 A AU3146997 A AU 3146997A
Authority
AU
Australia
Prior art keywords
protease inhibitors
hiv protease
pediatric formulation
pediatric
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU31469/97A
Inventor
Drazen Ostovic
Karen C. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9613109.9A external-priority patent/GB9613109D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU3146997A publication Critical patent/AU3146997A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
AU31469/97A 1996-06-03 1997-05-30 Pediatric formulation for hiv protease inhibitors Abandoned AU3146997A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1909796P 1996-06-03 1996-06-03
US60019097 1996-06-03
GBGB9613109.9A GB9613109D0 (en) 1996-06-21 1996-06-21 Pediatric formulation for HIV protease inhibitors
GB9613109 1996-06-21
PCT/US1997/009109 WO1997046222A1 (en) 1996-06-03 1997-05-30 Pediatric formulation for hiv protease inhibitors

Publications (1)

Publication Number Publication Date
AU3146997A true AU3146997A (en) 1998-01-05

Family

ID=26309555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31469/97A Abandoned AU3146997A (en) 1996-06-03 1997-05-30 Pediatric formulation for hiv protease inhibitors

Country Status (2)

Country Link
AU (1) AU3146997A (en)
WO (1) WO1997046222A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
BR0108433A (en) * 2000-09-05 2006-06-06 Abbott Lab flavoring systems for pharmaceutical compositions and methods for making such compositions
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
JPH0714872B2 (en) * 1990-02-06 1995-02-22 昭和薬品化工株式会社 Syrup composition
US5296604A (en) * 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent

Also Published As

Publication number Publication date
WO1997046222A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
AU3832895A (en) Thrombin inhibitors
AU3985897A (en) 1,3-diheterocyclic metalloprotease inhibitors
AU3102397A (en) Metalloprotease inhibitors
AU3140695A (en) 1h-indole-1-functional spla2 inhibitors
AU4762797A (en) Pharmaceutical compositions
AU2967597A (en) Pharmaceutical compositions
AU2523895A (en) Protein-scum remover
AU4723799A (en) Protease inhibitors
AU1795697A (en) Serine protease inhibitors
AU7139598A (en) Protease inhibitors
AU1877597A (en) Serine protease inhibitors
AU3777897A (en) Pharmaceutical compositions
AU692123B2 (en) 5alpha-reductase inhibitors
AU4092799A (en) Protease inhibitors
AUPM982594A0 (en) HIV protease inhibitors
AU1393900A (en) Morpholino-ethoxybenzofuran protease inhibitors
AU9110298A (en) Protease inhibitors
AU8673598A (en) Neuraminidase inhibitors
AU3146997A (en) Pediatric formulation for hiv protease inhibitors
AU9300298A (en) Protease inhibitors
AU1013997A (en) Amylase inhibitors
AU6828894A (en) Hiv protease inhibitors
AU2713100A (en) Protease inhibitors
AU4564499A (en) Protease inhibitors
AU4326197A (en) Pharmaceutical compositions